🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
542,50 USD
Máx. histórico
558,88
6 días
Split 2:1 del 24/08/2000
Caída desde máximo
-2,93%
Rango 52 semanas
406,67 – 568,67
Variación hoy
-1,19%
Cierre anterior
549,04
Rango de hoy
540,02 – 557,85
Volumen hoy
2.467.517
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 34,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 7 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 08/11/2005 | 24,49 | 24,72 | 24,08 | 24,57 | +0,33% | 2,61% | 1.299.000 |
| 07/11/2005 | 24,02 | 24,50 | 23,92 | 24,49 | +2,55% | 2,41% | 1.372.400 |
| 04/11/2005 | 23,88 | 24,23 | 23,14 | 23,88 | +0,38% | 4,56% | 1.095.400 |
| 03/11/2005 | 24,37 | 24,50 | 23,50 | 23,79 | -0,88% | 4,10% | 911.400 |
| 02/11/2005 | 23,41 | 24,47 | 23,30 | 24,00 | +2,78% | 5,00% | 1.514.100 |
| 01/11/2005 | 22,77 | 24,23 | 22,25 | 23,35 | +2,64% | 8,70% | 1.388.900 |
| 31/10/2005 | 21,70 | 22,98 | 21,70 | 22,75 | +4,84% | 5,90% | 884.600 |
| 28/10/2005 | 22,26 | 22,50 | 21,11 | 21,70 | -2,52% | 6,24% | 1.035.000 |
| 27/10/2005 | 22,27 | 23,10 | 22,20 | 22,26 | -0,62% | 4,04% | 1.167.900 |
| 26/10/2005 | 23,48 | 23,48 | 21,89 | 22,40 | -5,04% | 6,77% | 1.960.200 |
| 25/10/2005 | 23,55 | 24,00 | 23,27 | 23,59 | +0,43% | 3,10% | 963.600 |
| 24/10/2005 | 22,37 | 23,60 | 22,37 | 23,49 | +5,10% | 5,50% | 1.359.800 |
| 21/10/2005 | 22,30 | 22,62 | 21,53 | 22,35 | +0,22% | 4,89% | 1.519.400 |
| 20/10/2005 | 22,68 | 22,82 | 22,23 | 22,30 | -2,02% | 2,60% | 865.900 |
| 19/10/2005 | 22,47 | 22,80 | 21,40 | 22,76 | +0,93% | 6,23% | 1.185.200 |
| 18/10/2005 | 22,54 | 22,95 | 22,37 | 22,55 | -0,35% | 2,57% | 1.027.900 |
| 17/10/2005 | 22,82 | 23,06 | 22,00 | 22,63 | -0,31% | 4,65% | 1.048.500 |
| 14/10/2005 | 22,44 | 23,29 | 22,15 | 22,70 | +2,58% | 5,08% | 1.868.900 |
| 13/10/2005 | 20,86 | 22,15 | 20,80 | 22,13 | +6,45% | 6,47% | 2.654.800 |
| 12/10/2005 | 21,95 | 22,00 | 20,31 | 20,79 | -0,38% | 7,70% | 2.598.700 |
| 11/10/2005 | 21,36 | 21,70 | 20,60 | 20,87 | -1,97% | 5,15% | 1.231.500 |
| 10/10/2005 | 21,67 | 22,00 | 21,08 | 21,29 | -1,11% | 4,25% | 629.200 |
| 07/10/2005 | 21,28 | 22,55 | 21,02 | 21,53 | +1,17% | 7,19% | 1.540.900 |
| 06/10/2005 | 22,36 | 22,46 | 20,85 | 21,28 | -4,79% | 7,20% | 2.637.700 |
| 05/10/2005 | 24,44 | 24,52 | 22,34 | 22,35 | -8,33% | 8,92% | 2.719.300 |
| 04/10/2005 | 24,68 | 25,67 | 24,21 | 24,38 | +0,29% | 5,92% | 6.023.900 |
| 03/10/2005 | 22,40 | 24,51 | 22,30 | 24,31 | +8,77% | 9,87% | 3.675.700 |
| 30/09/2005 | 21,66 | 22,68 | 21,57 | 22,35 | +7,04% | 5,12% | 3.522.500 |
| 29/09/2005 | 19,53 | 20,97 | 19,53 | 20,88 | +7,19% | 7,37% | 2.347.400 |
| 28/09/2005 | 19,10 | 19,50 | 18,78 | 19,48 | +2,20% | 3,77% | 750.500 |